Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

AI-powered Imaging Biomarker May Predict IPF Lung Health, Survival

A novel imaging biomarker identified via an artificial intelligence (AI)-powered analysis could help predict lung function and survival outcomes for people with idiopathic pulmonary fibrosis (IPF). Brainomix, a U.K.-based software company, is developing a number of AI-based tools to analyze different diseases, including one called e-ILD…

Early Trial Data Indicates NP-120 Could Ease Coughing in IPF

Patients with idiopathic pulmonary fibrosis (IPF) with chronic cough who are being treated with the investigational oral medication NP-120 (ifenprodil) in a small clinical trial tended to experience a reduction in coughing, according to the therapy’s developer Algernon Pharmaceuticals. The company is funding an open-label Phase 2…

Cudetaxestat Well-tolerated in Esbriet, Ofev Combos in Phase 1 Trial

Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers when given in combination with other IPF treatments — specifically nintedanib and pirfenidone — in a Phase 1 study. “These findings provide confidence in the potential to safely co-administer cudetaxestat…

Enrollment Complete for Phase 2 Trial Testing Anti-fibrotic PLN-74809

Enrollment has been completed for INTEGRIS-IPF, a Phase 2a trial testing PLN-74809, an experimental oral anti-fibrotic therapy, in people with idiopathic pulmonary fibrosis (IPF). Pliant Therapeutics, the company developing PLN-74809 and sponsoring the trial, said it is expecting top-line results to become available midway through the year. The…

Ofev, Esbriet Found to Significantly Reduce Risk of Death in IPF

Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action — “offers protection” and can slow lung function decline in people with pulmonary fibrosis (PF), according to a new analysis. Moreover, the results showed that these medications can significantly reduce…

Chiesi Acquires Zampilimab, Antibody to Potentially Treat IPF

Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Under the agreement, Chiesi acquired global exclusive rights to develop and manufacture the potential antifibrotic therapy, and to market it should it be approved.

New Docuseries Highlights Efforts to Advance Care for Lung Diseases

The American Thoracic Society (ATS) has premiered a docuseries called “Helping the World to Breathe,” showcasing the society’s commitment to advancing care for people with lung diseases. Over 16 episodes, the series highlights stories from clinicians, researchers, and patients collaborating to advance care. For example, scientists and patients at…

NIH Funds Research Into Immune Mechanisms to Reverse Fibrosis

The National Institutes of Health (NIH) has awarded a grant to support research into immune mechanisms that could allow for the reversal of fibrosis, or tissue scarring, in idiopathic pulmonary fibrosis (IPF). The $469,034 award went to Narendiran Rajasekaran, PhD, and Archana Varadaraj, PhD, both of whom are assistant…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums